media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Yingen Biotech’s first innovative drug application for market launch

On April 9, the CDE website showed that Yingen Biotech’s first ADC drug, trastuzumab perconcave (DB-1303/BNT323), submitted a marketing application. This is Yingen Biotech’s first innovative drug to apply for market approval. In September 2025, the Phase III clinical trial (DYNASTY Breast02) of trastuzumab versus T-DM1 for the treatment of patients with HER2-positive unresectable or metastatic breast cancer who had previously received trastuzumab and taxane therapy met its primary endpoint, namely a significant prolongation of progression-free survival (PFS). Trastuzumab pac-ascorbic acid (TAA) is a clinical-stage HER2 ADC candidate that employs a stable, cleavable linker and a proprietary topoisomerase inhibitor-based payload design to reduce off-target toxicity and enhance antitumor activity, including bystander-killing effects. These characteristics may make PAC a potential new treatment option for patients with advanced HER2-expressing solid tumors, including those with both high and low HER2 expression. Trastuzumab perconcanava has received Fast Track and Breakthrough Therapy designations from the ...
- Source: drugdu
- 46
- April 10, 2026
Chia Tai Tianqing’s Pan-KRAS inhibitor TQB3205 receives dual clinical trial approval in China and the United States.

Following its approval for clinical trials in China in March, TQB3205, an innovative Class 1 oral Pan-KRAS inhibitor independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (a core subsidiary of Sino Biopharmaceutical Co., Ltd., received approval from the U.S. Food and Drug Administration (FDA) on April 4th (local time) to conduct clinical trials for advanced malignant tumors . The simultaneous acquisition of clinical access qualifications in both the U.S. and Chinese pharmaceutical markets signifies that TQB3205’s preclinical data and innovative mechanism of action have been recognized by internationally authoritative regulatory agencies, potentially providing a new “broad-spectrum treatment option” for pan-KRAS mutation patients worldwide. KRAS gene mutations are among the most common driver genes in human cancers, associated with approximately 30% of cancer cases worldwide, particularly prevalent in high-incidence cancers such as pancreatic cancer (approximately 90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%) [1-2] . For a ...
- Source: drugdu
- 49
- April 10, 2026
Filling a clinical gap! Dongyangguang Pharmaceutical’s marketing application for Vonoprazan injection has been accepted.

On April 8, 2026, the National Medical Products Administration (NMPA) accepted the marketing authorization application (NDA) for Dongyangguang Pharmaceutical’s independently developed improved new drug, vonoprazan fumarate sodium chloride injection (hereinafter referred to as “vonoprazan injection”). The indication for this drug is: treatment of peptic ulcer bleeding. The vonoprazan injection submitted for approval this time is an innovative dosage form developed based on the oral formulation vonoprazan fumarate tablets (trade name: Vocinti® ) , and is classified as a Class 2 new drug. The introduction of this injectable formulation effectively fills a clinical gap that oral formulations cannot meet, and is particularly suitable for high-risk patients with rebleeding peptic ulcers who are unable to take oral medication due to the severity of their condition. In addition, this drug is a ready-to-use large-volume infusion, which eliminates the need for on-site preparation in clinical use, effectively reducing the risk of contamination by pathogens ...
- Source: drugdu
- 39
- April 10, 2026
Breaking Through the “Irreversible” Petrification of the Heart – ATTR-CM Treatment Shifts from Defense to Counterattack

The story of transthyretin amyloid cardiomyopathy (ATTR-CM) begins with the structural instability of a protein. Under normal circumstances, TTR proteins transport thyroxine and vitamin A in the blood as tetramers, maintaining a stable structure and each fulfilling its function. However, under the influence of aging or specific gene mutations, the tetramer dissociates into monomers. These monomers misfold and aggregate into non-degradable amyloid fibers. Once these fibers deposit in the myocardial interstitium, the heart wall thickens and hardens, leading to decreased compliance, gradual loss of diastolic function, and ultimately heart failure. For a long time, the clinical approach to these diseases was essentially defensive, using drugs to stabilize the protein structure, slow down the deposition rate, and prolong the disease course as much as possible. As for the fibers already embedded in the myocardium, it was generally accepted that there was nothing that could be done. However, in recent years, this ...
- Source: drugdu
- 41
- April 10, 2026
China’s first to be approved for listing!

Today, GlaxoSmithKline (GSK) announced that its innovative biologic, Easily (demozimab) , has been approved by the NMPA for the treatment of adult patients with chronic sinusitis with nasal polyps (CRSwNP), making it the first and currently the only ultra-long-acting biologic in China for the treatment of chronic sinusitis with nasal polyps. It is worth noting that this comes only about 10 days after the drug was approved for maintenance treatment of severe eosinophilic asthma, marking the achievement of dual indications in the respiratory field in China for this world’s first IL-5 ultra-long-acting biologic that is administered once every six months . Chronic sinusitis with nasal polyps is a chronic upper respiratory tract disease characterized by type 2 inflammation , affecting approximately 30 million patients in China. Patients suffer from long-term symptoms such as nasal congestion, decreased sense of smell, facial swelling and pain, and sleep disturbances. Traditional treatments have significant ...
- Source: drugdu
- 40
- April 10, 2026
Several domestically produced FIC drugs will make their debut.

The American Association for Cancer Research (AACR) Annual Meeting is one of the largest and most influential academic events in the global oncology field. The 2026 AACR Annual Meeting will be held in San Diego, USA, from April 17 to 22, 2026. Currently, the AACR Annual Meeting has become an important platform for domestic innovative pharmaceutical companies to showcase their latest research results. At this year’s meeting, more than 100 Chinese pharmaceutical companies participated, presenting nearly 400 research results covering cutting-edge fields such as ADCs, bispecific antibodies, multi-antibodies, mRNA, and AI-driven drug development. Biocytogen will showcase 36 of its latest research findings in poster format, including various drug forms such as fully human monoclonal antibodies, bi/multispecific antibodies, monoclonal and bispecific antibody-drug conjugates (ADCs), nanobodies (VHHs), and TCR molecules, as well as 12 advances in preclinical animal models and pharmacological and efficacy studies. Veolia Biotech will announce the latest research results ...
- Source: drugdu
- 38
- April 10, 2026
【EXPERT Q&A】What standards need to be followed for clinical performance studies under the EU IVDR regulation?

Drugdu.com expert’s response: Under the EU’s In Vitro Diagnostic Regulation (IVDR), clinical performance studies must adhere to the following core standards to ensure the scientific validity, reliability, and compliance of the study results: I. Regulatory Framework and Core Requirements 1. IVDR Regulation (Regulation (EU) 2017/746) Clinical performance studies must comply with the requirements outlined in Articles 57-77 and Annex XIV of the IVDR, covering aspects such as study design, ethical review, subject protection, and data management. It is necessary to demonstrate the scientific validity, analytical performance, and clinical performance of in vitro diagnostic reagents (IVDs), ensuring their association with specific clinical conditions or physiological states. 2. ISO 20916:2024 Standard Core Role: As a harmonized standard under the IVDR, ISO 20916 provides a comprehensive framework for the planning, design, implementation, documentation, and reporting of clinical performance studies. Key Content: Presumption of Conformity: Compliance with the normative clauses of ISO 20916 is ...
- Source: drugdu
- 43
- April 10, 2026
Hologic Acquired for $18.3 Billion, New CEO Joins from Baxter

Hologic, a leader in breast health, in vitro diagnostics, gynecological surgery, and bone health, announced the completion of its go private acquisition led jointly by private equity giants Blackstone and TPG. At the same time, a key management transition was finalized: the company formally appointed José (Joe) E. Almeida, a veteran leader in the medical technology industry, as Chief Executive Officer, effective immediately upon announcement. This management change took place efficiently and in quick succession. Just one day earlier, on April 6, Hologic disclosed that Steve MacMillan, its long serving CEO, would retire upon completion of the privatization transaction. In a single day, this century old healthcare giant completed both its capital restructuring and leadership transition, officially entering a new phase of development. The high profile privatization deal was first agreed in October 2025, when Hologic reached a definitive acquisition agreement with funds managed by Blackstone and TPG. The transaction ...
- Source: drugdu
- 50
- April 9, 2026
China’s First CO₂ Contrast Injection Device Approved; Amed Medical Closes Over RMB 200M Series D Financing

Artery Network has exclusively learned that Amed Medical Devices (Beijing) Co., Ltd. (“Améd Medical” or “Amed”) has recently completed a Series D financing round of over RMB 200 million. The round was led by Zhesheng Collaborative Life Health Fund, with participation from Henan Key Intellectual Property Fund, Global Hedge Fund Management Co., Ltd., and other institutions. Following this financing, Améd Medical’s post-investment valuation exceeds RMB 1.5 billion. According to the company, the proceeds will mainly be used for the R&D and global registration of its core series of 3D-printed biodegradable vascular stents, as well as market promotion of its newly launched China-first CO₂ contrast injection device. Rising Demand for Vascular Interventions and the “Implant-Free Intervention” Trend Drive Rapid Growth of Biodegradable Stents and Interventional Auxiliary Devices Driven by population aging and other factors, the number of patients with cardiovascular diseases has grown rapidly. In China alone, the 2024 Report on ...
- Source: drugdu
- 53
- April 9, 2026
Haogrei Secures Tens of Millions of Yuan in Strategic Financing; Domestic Liquid Metal Bearing X ray Tubes Deployed in Multiple Class III A Hospitals

Recently, Haogrei Technology, an innovator focusing on core components for high end medical imaging, announced the completion of tens of millions of yuan in strategic financing. The round was jointly invested by Anhui Tongchuang Small and Medium sized Sci Tech Transformation Fund Partnership (L.P.), Shenzhen Tongchuang Angel Phase II Private Equity Venture Capital Fund Partnership (L.P.), Huzhou Nanhui Xunying Venture Capital Partnership (L.P.), and Huzhou Nanxun Xunying Venture Capital Partnership (L.P.). The proceeds will be used for large scale mass production and capacity expansion of core products, R&D investment in next generation technology platforms, recruitment of key talents, and construction of global marketing channels. Previously, Haogrei Technology had secured support from multiple leading institutions including Tongchuang Weiye, Yuanming Capital, and Su Venture Capital, with cumulative financing reaching nearly 100 million yuan. This fully demonstrates capital market confidence in its technical strength and the prospects of domestic substitution for core components ...
- Source: drugdu
- 54
- April 9, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.